Logo image of ARTV

ARTIVA BIOTHERAPEUTICS INC (ARTV) Stock Fundamental Analysis

NASDAQ:ARTV - Nasdaq - US04317A1079 - Common Stock - Currency: USD

5.36  +0.26 (+5.1%)

After market: 5.45 +0.09 (+1.68%)

Fundamental Rating

2

Taking everything into account, ARTV scores 2 out of 10 in our fundamental rating. ARTV was compared to 572 industry peers in the Biotechnology industry. While ARTV seems to be doing ok healthwise, there are quite some concerns on its profitability. ARTV has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ARTV has reported negative net income.
ARTV Yearly Net Income VS EBIT VS OCF VS FCFARTV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 -20M -40M -60M

1.2 Ratios

ARTV has a Return On Assets of -34.57%. This is in the better half of the industry: ARTV outperforms 61.78% of its industry peers.
ARTV has a better Return On Equity (-38.81%) than 71.90% of its industry peers.
Industry RankSector Rank
ROA -34.57%
ROE -38.81%
ROIC N/A
ROA(3y)-37.92%
ROA(5y)N/A
ROE(3y)-62.25%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ARTV Yearly ROA, ROE, ROICARTV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ARTV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARTV Yearly Profit, Operating, Gross MarginsARTV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 -1K -2K -3K

More info and screens

5

2. Health

2.1 Basic Checks

ARTV does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ARTV has about the same amount of shares outstanding.
There is no outstanding debt for ARTV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ARTV Yearly Shares OutstandingARTV Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 5M 10M 15M 20M
ARTV Yearly Total Debt VS Total AssetsARTV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 50M 100M 150M

2.2 Solvency

ARTV has an Altman-Z score of 1.46. This is a bad value and indicates that ARTV is not financially healthy and even has some risk of bankruptcy.
With a decent Altman-Z score value of 1.46, ARTV is doing good in the industry, outperforming 70.86% of the companies in the same industry.
ARTV has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.00, ARTV is in line with its industry, outperforming 49.74% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.46
ROIC/WACCN/A
WACC9.21%
ARTV Yearly LT Debt VS Equity VS FCFARTV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 11.33 indicates that ARTV has no problem at all paying its short term obligations.
ARTV's Current ratio of 11.33 is amongst the best of the industry. ARTV outperforms 84.12% of its industry peers.
A Quick Ratio of 11.33 indicates that ARTV has no problem at all paying its short term obligations.
The Quick ratio of ARTV (11.33) is better than 84.12% of its industry peers.
Industry RankSector Rank
Current Ratio 11.33
Quick Ratio 11.33
ARTV Yearly Current Assets VS Current LiabilitesARTV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 51.15% over the past year.
The Revenue has grown by 579.21% in the past year. This is a very strong growth!
EPS 1Y (TTM)51.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)579.21%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -25.60% on average over the next years. This is quite bad
ARTV is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -25.99% yearly.
EPS Next Y-339.32%
EPS Next 2Y-57.89%
EPS Next 3Y-25.6%
EPS Next 5YN/A
Revenue Next Year-99.19%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A

3.3 Evolution

ARTV Yearly Revenue VS EstimatesARTV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 10M 20M 30M
ARTV Yearly EPS VS EstimatesARTV Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -1 -2 -3 -4 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ARTV. In the last year negative earnings were reported.
Also next year ARTV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARTV Price Earnings VS Forward Price EarningsARTV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARTV Per share dataARTV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

A cheap valuation may be justified as ARTV's earnings are expected to decrease with -25.60% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-57.89%
EPS Next 3Y-25.6%

More info and screens

0

5. Dividend

5.1 Amount

ARTV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARTIVA BIOTHERAPEUTICS INC

NASDAQ:ARTV (3/7/2025, 8:05:38 PM)

After market: 5.45 +0.09 (+1.68%)

5.36

+0.26 (+5.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners84.84%
Inst Owner Change2.24%
Ins Owners0.73%
Ins Owner Change10.34%
Market Cap130.19M
Analysts85
Price Target21.42 (299.63%)
Short Float %6.58%
Short Ratio15.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-194.88%
Min EPS beat(2)-390.47%
Max EPS beat(2)0.71%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.18%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.33%
EPS NY rev (1m)0%
EPS NY rev (3m)3.87%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)366.64%
Revenue NY rev (1m)0%
Revenue NY rev (3m)33.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.86
P/FCF N/A
P/OCF N/A
P/B 0.65
P/tB 0.65
EV/EBITDA N/A
EPS(TTM)-3.52
EYN/A
EPS(NY)-3.08
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS1.39
BVpS8.27
TBVpS8.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -34.57%
ROE -38.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-37.92%
ROA(5y)N/A
ROE(3y)-62.25%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.33
Quick Ratio 11.33
Altman-Z 1.46
F-ScoreN/A
WACC9.21%
ROIC/WACCN/A
Cap/Depr(3y)460.97%
Cap/Depr(5y)N/A
Cap/Sales(3y)74.53%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-339.32%
EPS Next 2Y-57.89%
EPS Next 3Y-25.6%
EPS Next 5YN/A
Revenue 1Y (TTM)579.21%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-99.19%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
EBIT growth 1Y48.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y11.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.69%
OCF growth 3YN/A
OCF growth 5YN/A